Envista Holdings Corp (NVST)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
- Symbol
- NVST
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $3.88B
- 52 week range
- 18.77 - 30.42
Valuation
- Share price
- $23.82 (close of 2026-09-23)
- P/E (TTM)
- 40.98x
- Price to book
- 1.26x
- Price to free cash flow
- 15.65x
- Enterprise value
- $4.35B
- Book value per share
- $19.16
Price performance
| Period | Change |
|---|
| 1 day | +1.66% |
| 5 days | -3.68% |
| 1 month | -12.43% |
| 3 months | -5.70% |
| 6 months | -7.75% |
| Year to date | +9.72% |
| 1 year | +14.30% |
| 3 years | -14.41% |
| 5 years | -44.16% |
| All time | -14.78% |
Profitability and growth
- Return on equity
- 1.51%
- Return on invested capital
- 3.09%
- Return on assets
- 0.83%
- Return on capital employed
- 4.48%
- Gross margin
- 54.67%
- Net margin
- 1.73%
- EBITDA margin
- 12.21%
- Revenue growth
- 8.32%
- Net income growth
- 104.20%
- Free cash flow growth
- -23.89%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.39%
- Current ratio
- 2.43x
- Net debt to EBITDA
- 1.10x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $2.72B
- Cost of revenue
- $1.23B
- Gross profit
- $1.49B
- EBITDA
- $332.10M
- Net income
- $47.00M
- Earnings per share
- $0.28
- Research and development
- $114.00M
- Shares outstanding
- 168.00M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $2.72B | $1.49B | $47.00M | $0.28 |
| 2024-12-31 | $2.51B | $1.37B | $-1.12B | $-6.50 |
| 2023-12-31 | $2.57B | $1.44B | $-100.20M | $-0.60 |
| 2022-12-31 | $2.57B | $1.47B | $243.10M | $1.49 |
| 2021-12-31 | $2.51B | $1.43B | $340.50M | $2.11 |
| 2020-12-31 | $1.93B | $1.05B | $33.30M | $0.21 |
| 2019-12-31 | $2.28B | $1.35B | $217.60M | $1.60 |
| 2018-12-31 | $2.84B | $1.60B | $230.70M | $1.80 |
| 2017-12-31 | $2.81B | $1.62B | $301.10M | $2.35 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 54.67% | 1.73% | 1.51% | 3.09% |
| 2024-12-31 | 54.68% | -44.56% | -38.12% | -30.42% |
| 2023-12-31 | 56.13% | -3.90% | -2.40% | 0.32% |
| 2022-12-31 | 57.41% | 9.46% | 5.78% | 5.33% |
| 2021-12-31 | 56.86% | 13.57% | 8.39% | 6.89% |
| 2020-12-31 | 54.68% | 1.73% | 0.89% | 0.90% |
| 2019-12-31 | 59.05% | 9.52% | 6.14% | 3.82% |
| 2018-12-31 | 56.31% | 8.11% | 4.78% | 4.54% |
| 2017-12-31 | 57.68% | 10.71% | 0.00% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $1.21B | $1.45B |
| 2024-12-31 | $1.07B | $1.28B |
| 2023-12-31 | $940.00M | $1.40B |
| 2022-12-31 | $606.90M | $870.70M |
| 2021-12-31 | $1.07B | $883.40M |
| 2020-12-31 | $888.90M | $907.70M |
| 2019-12-31 | $211.20M | $1.32B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $230.40M | $37.60M |
| 2024-12-31 | $302.70M | $35.30M |
| 2023-12-31 | $217.50M | $30.70M |
| 2022-12-31 | $107.00M | $30.50M |
| 2021-12-31 | $306.90M | $28.20M |
| 2020-12-31 | $236.20M | $22.60M |
| 2019-12-31 | $319.70M | $18.40M |
| 2018-12-31 | $327.90M | $13.30M |
| 2017-12-31 | $310.20M | $12.30M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.36
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | $0.33 |
| 2026-05-06 | - | - |
| 2026-02-05 | - | - |
| 2025-10-29 | - | - |
| 2025-07-31 | - | - |
| 2025-05-01 | - | - |
| 2025-02-05 | - | - |
| 2024-10-30 | - | - |
Filings and sources
- Company website
- envistaco.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades